Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 8/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | USP14 | P54578 | 1/20 | 0.42 |
| ▸ | USP7 | Q93009 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16507031 | 0.85 | KMT2A (0.56) | HSD11B1ALDH1A1HDAC4KDM4ELMNA | |
| SCHEMBL16506928 | 0.85 | CHRM2 (0.57) | HSD11B1KDM4ESIGMAR1SMN1; SMN2OPRM1 | |
| SCHEMBL8351554 | 0.84 | USP2 (0.45) | HSD11B1ALDH1A1LMNASIGMAR1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL16507430 | 0.84 | MAPK1 (0.58) | HSD11B1ALDH1A1HDAC4KDM4ELMNA | |
| SCHEMBL16523531 | 0.83 | MEN1 (0.45) | HSD11B1ALDH1A1ATMNPC1 | |
| SCHEMBL19242638 | 0.82 | KMT2A (0.60) | HSD11B1ALDH1A1HDAC4KDM4ELMNA | |
| SCHEMBL16507502 | 0.82 | CHRM2 (0.60) | HSD11B1SMN1; SMN2OPRM1 | |
| Hydrochloric Acid SCHEMBL16507309 | 0.81 | CHRM2 (0.58) | HSD11B1OPRM1 | |
| SCHEMBL8351183 | 0.81 | HPGD (0.46) | HSD11B1ALDH1A1LMNASIGMAR1SMN1; SMN2 | |
| SCHEMBL8353497 | 0.81 | USP2 (0.45) | HSD11B1LMNASIGMAR1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015027058-A2 | CYCLOLKYL AMINE COMPOUNDS | PREXA PHARMACEUTICALS, INC. (US) | 2015-02-26 | — | — | WO | disclosed |
| US-20150057443-A1 | Cycloalkyl Amine Compounds | PREXA PHARMACEUTICALS, INC. | 2015-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057443-A1 | Cycloalkyl Amine Compounds | HCRTR2, HCRTR1, HTR2C | HSD11B1 422/4885ALDH1A1 887/4885HDAC4 3162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.